The UK subsidiary of Belgian drugmaker UCB (Euronext Brussels: UCB) said yesterday that it has agreed to collaborate on cutting-edge pharmaceutical research projects with Oxford University, enabling scientists from industry and academia to work together to develop innovative medicines to treat serious diseases in immunology and neurology.
These combined resources and expertise will give the best possible chance of turning innovative research into new medicines for patients, an area identified as a priority in the recent government Strategy for UK Life Sciences, said UCB.
Sir John Bell (Regius Professor of Medicine at Oxford University and former president of the Academy of Medical Sciences) and David Willetts (Minister for Universities and Science) joined Roch Doliveux (chief executive of UCB and chairman of the Innovative Medicines Initiative) and Ismail Kola (executive vice president and president of New Medicines at UCB) to sign the agreement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze